the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Myelodysplastic Syndrome (MDS) Cancer Clinical Trials
Interventional only

Phase II
Study No PI Title
IRB15-1373 Odenike, Olatoyosi Phase I/II and Pharmacological Study of Intravenous OTS167 in Patients with Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Details
IRB14-0702 Odenike, Olatoyosi A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS) Details
Phase I
Study No PI Title
IRB15-1373 Odenike, Olatoyosi Phase I/II and Pharmacological Study of Intravenous OTS167 in Patients with Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Details
IRB15-1285 Stock, Wendy A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects with Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Details
IRB14-0702 Odenike, Olatoyosi A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS) Details
IRB14-0331 Godley, Lucy A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents Details
Others
Study No PI Title
10-064-B Godley, Lucy Molecular characterization of hematopoietic malignancies
09-130-B Stock, Wendy A University of Chicago Leukemia Registry Protocol.


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .